Observational studyJournal of ovarian research2026
Socio-demographic profiles, motivations and perspectives of women undergoing publicly funded elective fertility preservation: a nationwide multicenter study in France.
Observational study in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07138469 (Overview of Elective Oocyte Preservation Three Years After Its Authorization in France), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Overview of Elective Oocyte Preservation Three Years After Its Authorization in France: a Nationwide Multicenter Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElective fertility preservation (EFP) is publicly funded in France, but little data is available about the socio-demographic profiles and motivations of women opting for this procedure, as well as on their perspective and levels of knowledge on the subject. To address this issue, a national multicenter study was conducted within the French CECOS network using an anonymous online questionnaire between November 2023 and June 2024 to women who had started of completed EFP process.
resultsA total of 351 responses were recorded. Most women requesting EFP were aged 33 years or older (87.2%), single (62.9%) and highly educated (95.4%). The main reason for choosing EFP treatment was the absence of a partner (50.7%). The main sources of information about EFP among women were their friends or family (37.6%), healthcare professionals (29.3%), and the media (27.1%). Regarding the future use of the cryopreserved oocytes, 68.5% of the women anticipated needing them. The intended family model primarily involved the use of cryopreserved oocytes within heterosexual couples (82.9%). Nevertheless, 42.6% of respondents also considered single motherhood. In the event of non-personal use, 65.8% of women would like to donate their oocytes. However, only 32.6% of women were aware of the French legal framework governing oocyte donation. Multiple correspondence analysis reveals two distinct clusters, which differ primarily in terms of fertility intentions and perspectives on oocyte use. Cluster 1 (48.1%, n = 169) comprises mainly single women who have completed the EFP procedure and wish to become pregnant and consider using their oocytes as single mothers. Conversely, Cluster 2 (44.7%, n = 157) comprises women with no prior experience of EFP, who were more likely to report a pregnancy despite not having immediate desire to become pregnant.
conclusionsThis is the first French multicenter study examining EFP in women, three years after its authorization and reimbursement by the national healthcare system. Our study reveals two distinct profiles among women choosing EFP and emphasizes the need to improve counseling strategies to ensure they meet women's needs during this procedure.
trial registrationNCT07138469 (accepted on June 25, 2025 on ClinicalTrials.gov).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.